Candida albicans (ATCC 10231), Systemic Model (IV Infection), LD90-100

ITEM 609010

CONTACT FOR PRICING

STATUS Available

CONTACT CUSTOMER SERVICE

^{ADD TO FAVORITES}

^{ADD TO PANEL}

OVERVIEW

DOCUMENTS/REFERENCES

RELATED SERVICES

RELATED PRODUCTS

BIOLOGICAL INFORMATION

BACKGROUND INFORMATION

This model assesses the efficacy of test articles at protecting against a lethal disseminated infection model of candidiasis. The procedure may be used to evaluate small molecules, vaccines and biologics. Candida albicans is a fungus that grows as yeast and as filamentous cells and causes opportunistic oral, genital, and systemic infections of humans. Strain ATCC 10231 is reported in the literature for infection models with rodents. It is susceptible to azoles and amphotericin B.

SPECIES

Candida albicans

ORGANISM

Fungi

INCUBATION CONDITIONS

Aerobic

SOURCE

STRAIN SOURCE

American Type Culture Collection (ATCC)

ASSAY INFORMATION

ASSAY TYPE

In Vivo

TESTING INFORMATION

PROCEDURE SUMMARY

Groups of 10 immune competent mice are used. Each animal is inoculated with an intravenous administered lethal (LD90-100) dose of pathogen. Test substance and vehicle are administered at specified time points following infection. Doses may be administered IV, SC, PO, IM, IP or by IV infusion. Mortality is recorded daily during the following 10 days. Prevention of mortality in 50 percent or more (>50%) of the animals indicates significant activity. The Minimum Effective Dose (MED) is defined as the dose that results in survival of 50% (or more) of the test animals.

CRITERIA FOR SIGNIFICANCE

≥ 50% of survival

TURNAROUND TIME

STANDARD

20 Days

CLINICAL RELEVANCE

THERAPEUTIC AREA

Infectious Disease

ADDITIONAL INFORMATION

BRAND

PDS

TESTING LOCATION

Taiwan - Taipei

OTHER INFORMATION

We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.